Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: 1st Quarter Results investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Markets
In a report released today, Jack Andrews from Needham assigned a Hold rating to Teradata (TDC – Research Report). The company’s shares closed last Wednesday at $39.88.
According to TipRanks.com, Andrews is a 5-star analyst with an average return of 24.6% and a 60.4% success rate. Andrews covers the Technology sector, focusing on stocks such as CommVault Systems, LiveRamp Holdings, and Pegasystems.
Teradata has an analyst consensus of Hold, with a price target consensus of $39.30, a 2.1% upside from current levels. In a report issued on April 8, Morgan Stanley also maintained a Hold rating on the stock with a $45.00 price target.
The company has a one-year high of $59.58 and a one-year low of $17.99. Currently, Teradata has an average volume of 2.43M.
Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition of GenMark underlines our commitment to help control infectious diseases and antibiotic resistance. Based on the results of the first quarter of 2021, we confirm the outlook for the full year.”
Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said:
“In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition of GenMark underlines our commitment to help control infectious diseases and antibiotic resistance. Based on the results of the first quarter of 2021, we confirm the outlook for the full year.”
Group sales increase 3%
1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc
Pharmaceuticals Division sales: As expected, significant impact from biosimilars (CHF -1.6 billion) Base effect from the strong first quarter 2020 (negative impact of the pandemic only since April 2020) Overall, this results in a 9% decline in sales.
Diagnostics Division sales:
Roche s contributions to the fight against the COVID-19 pandemic in the first quarter: SARS-CoV-2 Rapid Antigen Test Nasal to quickly identify people with the highest risk to be infectious (using simple nasal swabs) receives CE mark and special approvals for self-testing in several countries